Integrated Filing- Financial

Date: 31st July, 2026 The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001. Mumbai - 400 051. Security Code: 532815 Symbol: SMSPHARMA Dear Sir/Madam, Subject: Outcome of Board Meeting and Financial Results: With reference to the cited subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e., 31st July, 2026, have inter- alia, transacted the following item(s) of the Agenda: Financial Results 1. Approved the standalone and consolidated un-audited Financial Results along with Limited Review Report for the first quarter ended 30th June, 2026. Annual General Meeting, Book Closure and Record date 1. The 38th Annual General Meeting (AGM) of the company for the Financial Year 2025-26, is scheduled to be held on Wednesday, 23rd September, 2026 through Video Conference or Other Audio-Visual Means as per the Circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. 2. Approved the Notice of 38th Annual General Meeting (AGM) for the Financial Year 2025-26 and Directors Report along with annexures. 3. The Register of Member and Share Transfer Books of the Company will remain closed from Thursday, 17th September, 2026 to Wednesday, 23rd September, 2026 (both days inclusive) for taking record of the Members of the Company for the AGM. 4. The Company has fixed Wednesday 16th September, 2026 as the "Record Date" for the purpose of determining the Members eligible to receive dividend for the financial year 2025-26, if approved at the ensuing AGM and the same will be paid within the stipulated time period. Further, pursuant to Regulation 33 of the SEBI Listing Regulations, we enclose the following: Statement of un-audited (Standalone & Consolidated) Financial Results along with the limited review report issued by Statutory Auditors of the Company for the first quarter ended on 30th June, 2026. Re-appointment Managing Director of the Company 1. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the re- appointment of Mr. Ramesh Babu Potluri (DIN:00166381) as a Chairman and Managing Director (Promoter and Executive) of the Company for a term of 5 (Five) consecutive years effective from 01st October, 2026 till 30th September, 2031 (both days inclusive), be liable to retire by rotation. The said re-appointment is subject to the approval of the Shareholders of the Company. Mr. Ramesh Babu Potluri (DIN:00166381) is not disqualified from being re-appointed as a Managing Director in terms of the Companies Act 2013 and has given his consent to act as Managing Director. Further, in terms of BSE Circular bearing Reference No. LIST/COMP/14/2018-19 and NSE Circular bearing Reference No. NSE/CML/2018/24 dated June 20, 2018, we have received confirmation from Mr. Ramesh Babu Potluri, he is not debarred from accessing capital markets and / or restrained from holding the office of director by virtue of any order of the SEBI or any other such authority. The details as required in terms of Regulation 30 and Schedule III of the SEBI Listing Regulations, read with SEBI Circular SEBI/HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure I. Giving loan to Subsidiary Approved to give loan to SMS Peptides Private Limited, Subsidiary Company, up to an aggregate amount not exceeding Rs. 50 Crores, in one or more tranches, subject to approval of shareholders at the ensuing the general meeting, pursuant to Section 185 of the Companies Act, 2013. The details as required in terms of Regulation 30 and Schedule III of the SEBI Listing Regulations, read with SEBI Circular SEBI/HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure II. The meeting commenced at 3.00 p.m. and concluded at 04:20 p.m. Please take the above intimation on your records. Thanking you Yours faithfully For SMS Pharmaceuticals Limited Thirumalesh Tumma Company Secretary & Compliance Officer SMS PHARMACEUTICALS LIMITED I (CIN : L24239TG1987PLC008066) Regd. Office: 8th Floor, Trendset Jayabheri Connect, Kondapur,Serilingampally, Ranga Reddy Dist., Hyderabad-500084.Telangana. India. Tel: +91-40-6985 9999, Fax :+91-40-2525 9889 ; Email: complianceofficer@smspharma.com Standalone Statement of Unaudited Financial Results for the Quarter ended 30th June, 2026 (Rs. In Lakhs) Quarter ended Year ended S.No Particulars 30/06/2026 31/03/2026 30/06/2025 31/03/2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Income (a) Revenue from Operations 20,696.49 23,794.75 19,604.71 88,687.10 (b) Other Income 174.44 257.44 59.31 835.38 Total Income 20,870.93 24,052.19 19,664.02 89,522.48 2 Expenses (a) Cost of Materials Consumed 13,572.13 12,831.07 14,591.55 51,687.27 (b) Changes in Inventories (2,384.73) 500.89 (3,568.83) (2,284.17) (c) Manufacturing Expenses 1,951.54 2,344.83 1,972.72 9,070.22 (d) Employee Benefits Expense 2,330.42 2,943.49 1,818.49 8,792.34 (e) Finance Cost 549.95 527.67 584.04 2,307.56 (f) Depreciation and Amortization Expense 999.08 1,013.09 975.25 3,991.93 (g) Other Expenses 1,038.12 1,186.59 904.62 4,330.20 Total Expenses -(a to g) 18,056.51 21,347.63 17,277.84 77,895.35 3 Profit/(Ioss) Before Exceptional and Extraordinary Items and Tax (1-2) 2,814.42 2,704.56 2,386.18 11,627.13 4 Exceptional items - - - - 5 Profit/(loss)Before Extraordinary Items and Tax (3-4) 2,814.42 2,704.56 2,386.18 11,627.13 6 Extraordinary Items - - - - 7 Profit/(Ioss) Before Tax (5-6) 2,814.42 2,704.56 2,386.18 11,627.13 8 Tax Expenses (a) Current Tax relating to Current Period 610.00 548.00 500.00 2,598.00 (b) Current Tax relating to Earlier Period - (4.69) - (4.69) (c) Deferred Tax 91.16 69.16 65.43 272.89 Total Tax Expense 701.16 612.47 565.43 2,866.20 9 Net Profit / (Loss) after Tax (7-8) 2,113.26 2,092.09 1,820.75 8,760.93 10 Other Comprehensive Income (OCI): Items that will not be reclassified to profit or Loss: (i) Remeasurement gains/(Iosses) on defined benefit plans (10.00) 31.32 (12.61) 4.43 (ii)lncome Tax effect on the above 2.52 (7.88) 3.17 (1.12) Total Other comprehensive Income/(Ioss),net of tax (7.48) 23.44 (9.44) 3.31 11 Total Comprehensive Income (9+10) 2,105.78 2,115.53 1,811.31 8,764.24 12 Paid-up equity share capital (Face Value of Re.1/-each) 936.52 936.52 886.52 936.52 13 Other Equity excluding revaluation reserves 79,542.17 14 Earnings Per Equity Share of (Face Value of Re.1/-each) 2.26 2.29 2.05 9.58 Basic / Diluted (not annualised) Notes: 1 The above standalone unaudited financial results have been reviewed by the Audit Committee on July 31, 2026 and approved by the Board of Directors at its meeting held on July 31, 2026. The Statutory Auditors of the Company have carried out a limited review on standalone financial results and have issued an un-modified conclusion in respect of the limited review for the limited review for the quarter ended June 30, 2026. 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 (lithe Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI). 3 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108. 4 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the unaudited published year to date figures up to third quarter of the financial year ended March 31, 2 [Showing first 8,000 characters — download PDF for full document]